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Abstract Contact allergies are complex diseases, and
one of the important challenges for public health and
immunology. The German ‘Federal Institute for Risk
Assessment’ hosted an ‘International Workshop on Contact
Dermatitis’. The scope of the workshop was to discuss
new discoveries and developments in the field of contact
dermatitis. This included the epidemiology and molecular
biology of contact allergy, as well as the development
of new in vitro methods. Furthermore, it considered regu-
latory aspects aiming to reduce exposure to contact
sensitisers. An estimated 15–20% of the general population
suffers from contact allergy. Workplace exposure, age, sex,
use of consumer products and genetic predispositions were
identified as the most important risk factors. Research
highlights included: advances in understanding of immune
responses to contact sensitisers, the importance of autoxi-
dation or enzyme-mediated oxidation for the activation of
chemicals, the mechanisms through which hapten-protein
conjugates are formed and the development of novel in
vitro strategies for the identification of skin-sensitising
chemicals. Dendritic cell cultures and structure-activity
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relationships are being developed to identify potential
contact allergens. However, the local lymph node assay
(LLNA) presently remains the validated method of choice
for hazard identification and characterisation. At the
workshop the use of the LLNA for regulatory purposes and
for quantitative risk assessment was also discussed.
Keywords Contact allergy  Dermatitis  Epidemiology 
Molecular mechanisms  Regulatory aspects
Introduction
The prevalence of contact allergy is rising worldwide [1–
3]. This results in high costs for health care systems and the
economy as well as in an impairment of the quality of life
for the patients. The German ‘Federal Institute for Risk
Assessment’ (BfR) invited national and international
experts from the field of contact dermatitis for a 2-day
workshop in Berlin, Germany. The workshop was organ-
ised as a part of the ‘action plan against allergies’, initiated
by the German ‘Federal Ministry of Food, Agriculture and
Consumer Protection’ (BMELV). The aim of the workshop
was to provide a better understanding of allergic skin
reactions by summarising the current state of research and
to elucidate prevention strategies, as well as the require-
ment for any further regulation. The first day emphasised
the magnitude of the problem in the general population,
highlighted possible prevention strategies, and summarised
known cellular and molecular mechanisms of contact
allergy. The second day focused on new in vitro methods
for assessing allergen potency and on regulatory aspects of
contact allergy.
The epidemiology of contact dermatitis: prevalence,
correlations and molecular markers
Allergy incidence and prevalence
In Europe about 20% of the general population suffers
from contact allergy to at least one contact allergen.
Most common are allergies to nickel, fragrances and
preservatives. Allergic reactions to chromate and p-phen-
ylenediamine (PPD) are generally less common but occur
frequently in occupationally exposed subgroups of the
population [4]. Contact dermatitis occurs twice as fre-
quently in women as in men [4] and often starts at a young
age, with a prevalence of 15% in 12–16 year olds (Fig. 1)
[5].
Of major concern is occupational contact dermatitis
(OCD), which ranks first among occupational diseases in
many countries [6]. The reported annual incident rate for
OCD is 0.5–1.9% [7]. However, incidences are likely to be
underestimated because of underreporting and lacking
registration for milder cases of skin disease [8]. Moreover,
the notification systems differ amongst countries, as do
the criteria for compensation. In a Bavarian study, about
a third of patients registered with OCD were severely
professionally affected, facing either retraining or unem-
ployment. The most affected professions (*80%) were
metal workers, hairdressers, health care workers, employ-
ees in the food industry, cleaners, construction workers and
painters [9].
Nickel Nickel is one of the major contact allergens
worldwide. Therefore, the European Union (EU) restricted
its use in consumer products in 1994 [10]. As a result
nickel allergy among young patients showed a decline in
several countries such as Germany [11], Sweden [12] and
Denmark [13]. In Denmark the frequency of nickel aller-
gies dropped from 26.9% before the EU directive to 12.4%
thereafter [13]. However, despite the initial decline nickel
sensitisation is still frequent among young women in
Germany, probably due to insufficient protection [14].
Further on a significant number of people are still exposed
to nickel, mainly in their working environment [15] and
new sources of nickel exposure, such as mobile phones,
have been reported recently [16]. Nevertheless, in the
absence of legislative regulation for the use of nickel (e.g.
in the US) the prevalence of nickel allergy is still
increasing, especially among women [1].
Fragrances Fragrance allergy is among the most fre-
quently detected allergies in the general population and has
a prevalence ranging from 1.0–4.2% [17]. About a third
of all allergies against cosmetic products are caused by
fragrance allergies. Fragrances are complex mixtures
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comprising altogether more than 2,000 substances, many of
which are contact allergens. A mix of eight substances,
fragrance mix I, has routinely been used to detect fra-
grance-mediated contact dermatitis. This mix has now been
supplemented with a second mix of five compounds, called
fragrance mix II [18]. Recent years saw a decline in allergy
prevalence against fragrance mix I. Nevertheless, there
remain a high number of reported cases with acute eczemas
caused by fragrances [19–21]. The frequency of fragrance
allergies is increased further by the autoxidative formation
of allergens from commonly used fragrances [22–24].
A fragrance allergen with increasing prevalence is hy-
droxyisohexyl 3-cyclohexene carboxaldehyde (HICC). It is
extensively used in deodorants [25] and has been linked to
strong allergic reactions in users [26]. Hence HICC is now
one of 26 fragrance chemicals recognised as contact
allergens that is required to be labelled when present in
cosmetic products and detergents (household products)
[27]. This list is currently being reviewed.
Chromium Contact dermatitis against chromium (CrVI)
has been a recognised problem in the occupational setting,
with a prevalence of e.g. 17% in cement workers during the
construction of the channel tunnel connecting continental
Europe with Britain [28]. Therefore, the EU regulated the
content of chromium in cement in 2005 and sensitisation to
chromate in construction workers has since declined [29,
30]. However, this regulation does not include leather
products such as shoes, where an increasing incidence
has been recognised [31]. In Germany, though, the sale
of consumer products with skin contact is banned if
they release detectable amounts of CrVI (ordinance of
commodities).
p-Phenylenediamine (PPD) Allergic reactions caused by
oxidative hair dye ingredients (e.g. PPD) are of special
concern because of their severity and the widespread use of
hair dyes. An estimated 0.2–2.5% of the European popu-
lation and up to 20% of hairdressers suffer from hair dye
allergies [32]. One risk factor for sensitisation to PPD in
the general population is black henna tattoos with illegally
added PPD [33–35]. Of further concern are cross-reacting
substances closely related to PPD, such as the hair dye
toluene-2,5-diamine (PTD) or the antioxidant isopropyl-
phenyl p-phenylenediamine (IPPD) [36].
Risk factors
Risk factors for allergic contact dermatitis (ACD) can
be subdivided into acquired and inherent. Acquired risk
factors are generally inflammatory skin diseases such as
irritant contact dermatitis (ICD), stasis dermatitis and
possibly atopic dermatitis, while inherent risk factors are
genetic variances resulting in a higher susceptibility
(Fig. 1).
Acquired risk factors ICD often precedes ACD. Usually
ICD results from a breakdown of the barrier function of the
skin after exposure to skin irritants. Approximately 10% of
the population suffer from ICD. The most common causes
are wet work, hand washing and the wearing of occlusive
rubber gloves. Atopy is a well recognised risk factor for
ICD and thus possibly also for ACD [37]. However, recent
studies on the gene polymorphisms of filaggrin published
conflicting results regarding the question if ICD is a purely
acquired risk factor [38, 39]. It seems likely that ICD has
an inherent basis [40, 41].
Stasis (or leg) dermatitis is caused by venous insuffi-
ciency rather than allergens. Nevertheless, after adjusting
for confounders such as sex, age and atopic dermatitis, leg
© European Union 2011, http://europa.eu/abc/maps/index_en.htm
EU-population: ~ 500 Million
36 x 106
72 x 106
frequent allergens are
metals (i.e. Ni, CrVI) > fragrances > dyes
Risk factors
Inherent
(i.e. genes, age, sex and ethnicity)
Acquired
(i.e. skin diseases or multisensitisation)
irritant contact
dermatitis
leg stasis
atopic
eczema
Prevention of dermatitis in the occupational setting by surveillance,
introduction of good working practices (e.g. hair dressers) and legislation
(e.g. European nickel directive and limits for chromium in cement).
Fig. 1 Allergic contact dermatitis in the European Union, incidence
and preventive measures
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stasis could be identified to increase the risk for ACD
against distinct allergens significantly [42]. Another inde-
pendently acquired risk factor that was identified by
regression analysis is multisensitisation. The risk of contact
allergy to a specific allergen increases with the number of
positive reactions in patch testing [43]. It was further
shown that polysensitised individuals reveal stronger
reactions to patch tests [44] and that there is an association
between polysensitisation and sensitisation to weak aller-
gens [45].
A further potential risk factor is atopic eczema, which
often results in a reduced skin barrier function and there-
fore facilitates the penetration of toxins and allergens.
However, differences in the immunological response in
patients with atopic eczema frequently seems to mitigate
some of the observed effects [46].
Inherent risk factors Genes, age, sex and ethnicity are the
main inherent risk factors in regard to susceptibility for
ACD.
Genetic risk factors are based on variations in genes (e.g.
polymorphisms) involved in relevant steps for the develop-
ment of contact dermatitis. Genetically influenced steps are
the antigen uptake through the skin barrier, the antigen-spe-
cific response by immune cells or the metabolism of antigens
by cutaneous enzymes [for a comprehensive review refer to
ref. 47]. An example for the latter is the metabolism and
possible activation of antigens by epidermal N-acetyltrans-
ferases (NATs). Studies found a relationship between the
genetic polymorphism for these phase II enzymes and the risk
for contact dermatitis. Patients with contact dermatitis tended
to have NATs with a higher than average enzymatic activity
[48, 49]. Other studies link the allele for a rapid acetylating
NAT1 to a lower susceptibility for PPD sensitisation [50].
Similarly, a homogenous deletion of the glutathione S-
transferases (GSTs) M1 and T1 showed an association with
increased sensitisation against the preservative thimerosal
[51]. The role of GSTs was confirmed in another study
showing an elevated risk for chromate sensitisation in cement
workers with a GST-T1 null phenotype [52]. Cytokine gene
polymorphisms represent possible genetic risk factors at the
level of an immunologic response [53]. Mutation of the
promoter for tumour necrosis factor a at position 308 is
associated with a higher susceptibility for chromate sensiti-
sation in cement workers [52]. Likewise, the homozygous
allele interleukin (IL) 16-295C is found more frequently in
polysensitised individuals with ACD [54]. Other gene poly-
morphisms increasing the risk for ACD have been observed
in coding regions of enzymes, i.e. angiotensin-converting
enzyme [55]. Induction and elicitation of contact dermatitis
decline with increasing age [due reduced immune functions,
see ref. 56], whereas the frequency of sensitisation increases
[42].
The sex prevalence of ACD in the German population is
reported to be 8% in men and 21% in women [57]. The
more than two-fold higher prevalence in women is due to
different exposures, such as nickel through piercing [13,
58]. However, even if nickel is not considered, women still
have a higher prevalence for ACD. This higher suscepti-
bility is probably caused by hormonal influences [59, 60].
Boys on the other hand show a higher prevalence for
allergic skin reactions against fragrances [61].
Studies investigating the relation between ACD and
ethnicity are inconclusive in regard to ethnicity as an
inherent risk factor [e.g. ref. 62]. Some reports implicate
darker skin to have a higher barrier function for some
substances, thus lowering the respective risk for ACD [63,
64].
Risk factors in the occupational setting Atopic skin
diathesis (ASD) was recognised as a major risk factor for
OCD [65]. Data analysed from a registry of occupational
skin diseases in Bavaria showed that 37% of patients with
OCD also suffered from ASD [66]. Cohort studies subse-
quently identified several professional risk factors for the
development of OCD. In the car industry the most impor-
tant risk factors were ASD, a history of hand eczema and
more than 3 h wet work per day [67]. Likewise hairdressers
were significantly affected, with 59% developing hand
eczema during their first year of apprenticeship. Again,
ASD and wet work (4 h) were identified as the statistically
most significant risk factors (p \ 0.001, T.L.D., personal
communication).
Similar results come from studies with nurses, where
ASD together with hand washing and disinfection was a
significant risk factor (p \ 0.001) for the development of
hand eczema (T.L.D., personal communication). This is in
line with the findings of studies looking into the causes of a
recent epidemic of ICD in health care workers in the UK’s
national health system (NHS). Health care workers in the
UK wash their hands up to 60 times a day as a result of the
NHS’ ‘Clean Hands Campaign’, which was introduced to
reduce microbial cross infections, especially with multi-
drug resistant Staphylococcus aureus. As a result there has
been a two-fold increase in the amount of hand cleansing
soap purchased by the NHS in the past 4 years, while the
amount of alcohol gel purchased is a tenth of what health
care providers in continental Europe tend to use. In order to
lower the risk for ICD, educational hand cleansing cam-
paigns should thus emphasise the need to use alcohol gels
rather than hand washing (J.E., personal communication).
Prevention
Surveillance is the basis of prevention [68], and there-
fore population-based investigations in consumer and
766 M. Peiser et al.
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occupational settings are important. However, they cannot
provide a tool for continuous monitoring. They have to be
complemented by clinical epidemiological data, which
indeed are collected in many countries. This has previously
been the basis for successful interventions such as the
nickel regulation [10] or the ban of the preservative
methyldibromo glutaronitrile (MDGN) [69].
Prevention of OCD Occupational contact dermatitis fre-
quently occurs because of lack of awareness of dermatitis
hazards, complacency and poor working practices. There
are various approaches to prevent OCD. Generally speak-
ing ‘general primary prevention’, that is the elimination,
replacement or reduction of allergenic substances, is by far
the most effective approach [e.g. 36, 70]. Alternatively,
exposure to harmful substances could be minimised by
avoiding their release from the corresponding product, e.g.
by encapsulation. Other preventive measures include the
reorganisation of work, for example reducing the hours of
wet work in order to minimise the risk for hand eczema
(Fig. 1).
Efforts to minimise risk factors for OCD should be
complemented by the use of personal protective equipment
and pre-employment screening. In Germany, prevention
measures are described in the ‘‘Approved Code of Prac-
tice’’ (TRGS) regulations. For hairdressers these include
the replacement of harmful substances und instructions on
the use of personal protective equipment (e.g. gloves). As a
result the annual incidence of OCD in hairdressers dropped
significantly [70, 71]. Skin care management should
include preventive skin protection as well as skin care after
hand cleansing [72]. Recommendations for the minimisa-
tion of work-related hand eczema include the washing of
the hands with lukewarm water, the use of appropriate
gloves for the shortest possible time, the removal of hand
jewellery prior to work, the wearing of cotton liners when
possible and the avoidance of disinfectant hand cleansers.
Creams should be applied after work and at home [73].
Molecular mechanisms of chemically induced
contact dermatitis
Innate immune mechanisms involved in contact dermatitis
Dendritic cells (DCs) and the local tissue microenviron-
ment are crucial factors in the development of ACD.
Within the immune system DCs are the cell type that
primes naı¨ve T cells and thus forms a crucial link between
the innate and adaptive immune system.
The precise role of DCs in ACD is still under investi-
gation; especially the contributions of the respective
cellular pools are still disputed. In the current model
Langerhans cells (LCs), as epidermal DCs, and dermal DCs
are centrally involved in the sensitisation and the elicitation
phases of ACD (Fig. 2). During sensitisation, DCs react to
potentially allergic chemicals by interaction with neigh-
bouring keratinocytes, migration to the local draining
lymph nodes and the priming of naı¨ve T cells. These
reactions are mediated by inflammatory cytokines, che-
mokines and adhesion molecules [74]. Allergen-specific
effector T cells are then recruited into the skin upon contact
with the same allergen (elicitation). Following their
recruitment these T cells are activated by allergen-pre-
senting skin cells, including LCs, dermal DCs and most
likely keratinocytes [75]. Cytotoxic effector T cells in the
epidermal-dermal border then deliver an inflammatory
‘lethal hit’ killing, amongst others, keratinocytes at the
suprabasal layer [76]. The following activation of further
skin-specific effector cells, i.e. cytotoxic T (CD8? Tc1)
cells and T helper (Th) cells 1 and 17, results from the
interaction of DCs, keratinocytes and the loss of regulatory
T (Treg) cell-mediated inhibition [77, 78].
The priming of naı¨ve T cells in skin is the result of a
molecular signal cascade originating from skin DCs. The
latter present antigenic peptides or allergens on their major
histocompatibility complex molecules (MHC) for recog-
nition by antigen specific T cell receptors (TCRs).
Concomitantly there is co-stimulation of the T cell popu-
lation, e.g. by the interaction of DC-expressed CD80/CD86
and CD28 on T cells. Cytokines excreted by the DCs (e.g.
IL-12, IL-6) polarise the T cell subset differentiation. This
leads to the loss of regulatory T cell inhibition, as well as
the generation of Th cells 1, 2, 3 and 17, CD8? Tc1 cells
and most likely other subsets. Finally the expression of T
cell homing receptors (e.g. E-selectin ligand, CCR4 and
CCR10) is induced by migratory DCs in the draining
lymph nodes. Primed T cells will subsequently home into
the tissue of origin of the corresponding DCs, e.g. the skin
in case of dermal DCs and LCs [79, 80]. Skin DCs acquire
their potential to imprint tissue-specific homing receptors
in CD8? Tc1 cells by interaction with stromal and epi-
thelial cells. In cocultures of DCs with dermal fibroblasts,
DCs are prompted to imprint skin homing receptors on T
cells [81].
In humans ACD has been associated with defective Treg
cells [82, 83] and indeed it has become clear that Treg cells
influence sensitisation as well as elicitation. Originally Treg
cells were defined as CD4?CD25?-T cells and were
mainly associated with self-tolerance [84, 85]. We now
know that this definition comprises a heterogeneous cell
population that includes natural Treg and inducible Treg
cells under the transcriptional control of Foxp3 as well as
Tr1- and Th3-cells [reviewed in refs. 86, 87]. The skin
contains predominantly inducible Treg cells, which can be
triggered by LCs as well as dermal DCs [88, 89]. However,
the precise phenotypes of Treg cells involved in ACD are
Allergic contact dermatitis: epidemiology, molecular mechanisms 767
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still not known [87]. Recently the induction of contact
allergen-specific CD4?CD25?ICOS? Treg cells during
sensitisation was shown to be an important regulator of
CD8? effector T cell responses in contact hypersensitivity
[90]. Following exposure to a contact allergen Treg cells
can lower or even completely suppress the process of
sensitisation [89, 91–93]. During subsequent elicitation
they can further downregulate the immune response (i.e. by
CD39) and influence the influx of leukocytes (mediated by
IL-10) [94, 95]. Finally, Treg cells are involved in the
control and eventually termination of the inflammatory
response [96].
The innate stress and immune response preceding the
induction of skin homing T cells is triggered by several
complex interactions of contact allergens with the skin
and partly resembles the innate immune response to
pathogens. This involves the triggering of Toll-like
receptors, induction of reactive oxygen species and acti-
vation of the NLRP3 inflammasome [97]. As a cytosolic
complex the latter consists of the innate immune receptor
NLRP3, the adaptor protein ASC and pro-caspase-1. Its
activation is the result of allergen-induced ATP-release
from skin cells and triggering the ATP receptor P2X7
[98–100]. Subsequently this leads to release of active
caspase-1, which processes contact allergen-induced pro-
IL-1b and pro-IL-18 to the mature and secreted cytokines.
These cytokines are involved in the inflammation of the
skin and trigger migration of DCs, thus mediating a
‘danger’ signal function for contact sensitisers [101, 102].
Knock out studies in mice further confirm this signal
function for contact sensitisers. Recent studies show that
Toll-like receptor (TLR) deletion mutants (DTLR 2/DTLR
4 or, alternatively, DTLR 2 or 4/DIL-12Rb2) can not be
sensitised to 2,4,6-trinitro-1-chlorobenzene (TNCB) and
other contact allergens. In the absence of TLR2- or TLR4-
mediated signalling DCs are only partially activated by
contact allergens, upregulating co-stimulatory molecules
but no pro-inflammatory cytokines [103]. While TNCB
activates TLR2 and TLR4 indirectly through the induction
of endogenous TLR2/4 ligands, nickel can trigger TLR4
signalling directly. Nickel ions can interact with histidine
residues in human TLR4. Interestingly, these histidine
residues are missing in the mouse TLR4. This explains
why mice do not develop contact hypersensitivity to
nickel unless LPS is co-injected [104]. These new findings
show a physiological role for TLRs in the induction of
contact hypersensitivity.
Furthermore, contact allergens can induce the cytopro-
tective phase II response. The phase II response is activated
by the binding of electrophilic contact allergens to the
cysteine-rich sensor Kelch-like ECH-associated protein
(Keap1). This results in the release and nuclear transloca-
tion of the transcription factor Nrf2, thereby leading to the
activation of genes that contain antioxidant response ele-
ments [105]. Thus the Keap/Nrf2 pathway modulates
inflammation and other responses of the cell. Contact
sensitisers like 1-chloro-2,4-dinitrobenzene, p-phenylene-
diamine and NiSO4 are potent inducers of the Keap/Nrf2
pathway in DCs, suggesting Nrf2 may be a new biomarker
for the sensitisation potential of chemicals [106].
The detailed understanding of the induction of innate
stress and immune responses by contact allergens will help
to develop new therapeutic strategies to treat ACD, to
identify potential contact allergens and to discriminate
them from irritants. Another goal is to develop in vitro
assays for hazard identification and risk assessment in order
to replace animal testing.
The skin immune system and contact dermatitis:
role of keratinocytes and NKT cells
Until recently the classical paradigm stated LCs to be the
primary antigen presenting cells for T cell responses in
skin. The importance of LCs being undisputed, this state-
ment had to be revised to include the aforementioned DCs
and, most likely, keratinocytes. Meanwhile there has been
increasing evidence that LCs might also control the T cell
response by secretion of anti-inflammatory cytokines (IL-
10 and TGF-b) and the induction of regulatory T cells [88,
107, 108]. Accordingly, following treatment with oxazo-
lone or 2,4-dinitro-1-fluorobenzene (DNFB) mice with
ablated LCs show increased ear swelling [109].
In this context keratinocytes may as well play an
important role in downregulating the skin’s immune
responsiveness in steady state and may interfere with the
induction of contact hypersensitivity. Only low levels of
the inflammation-stimulating ligand B7 are expressed by
keratinocytes during steady state. However, elevated levels
of B7-1 (CD80) were found in keratinocytes transfected
with B7-1 reporter constructs after exposure to allergens
like oxazolone, Myroxylon pereirae (Balsam of Peru) or
nickel chloride [110]. Keratinocytes from transgenic mice
(B7-1 and B7-2) delivered costimulating signals for skin
inflammation during ACD. After treatment with TNCB or
DNFB, B7-1 transgenic mice showed pronounced ear
swelling and elevated levels of the cytokines IL-6, TNF-a
and LT-b. Furthermore, the expression of IL-10 and the
hapten specific IgE is seen in B7-1 transgenic mice but
absent in B7-2 (CD86) or wild-type (wt) mice. This
inflammatory response is typical for Th1 reactions in
chronic dermatitis [111]. The elicitation of ear swelling by
the hapten-specific IgE indicates a deviated Th2-mediated
immune response, even in the presence of Th1 specific
cytokines [111, 112]. In wt mice keratinocytes thus seem
to modulate T cell-mediated inflammation and induce
immune tolerance by T cell anergy.
768 M. Peiser et al.
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Further, keratinocytes are most likely the main source of
IL-33 in the epidermis. This proinflammatory member of
the IL-1 family is found in high concentrations in barrier
tissues [113–115]. Located in the nuclear compartment of
keratinocytes IL-33 is discussed to be an alarmin released
by necrotic cells and was found to exacerbate contact
sensitivity [113, 116]. The precise function of IL-33 is
unkown. However, IL-33 is known to activate the ST2-
1RAcP receptor complex, thus triggering activation of NF-
jB [117, 118]. Further on IL-33 was found to enhance IL-5
production by Th2 cells and to induce the proliferation of
B1 lymphocytes independent of IL-5. The respective
studies indicate both effects to be ST2-mediated [116,
119]. The IgM secreted by B1 cells is not only reactive to a
broad range of antigens, but also is required for the initi-
ation of antigen specific T-cell migration [74, 116]. B1 B
cells have been shown to participate in the early initiation
phase of contact hypersensitivity by IgM-mediated facili-
tation of effector T cell recruitment for elicitation.
Sensitisation with a contact allergen leads to rapid activa-
tion of natural killer T lymphocytes (NKT cells) in the
liver. These then activate peritoneal B1 B cells via IL4,
recruiting them to lymphoid organs [120–122].
Natural killer T lymphocytes are known to be crucial for
autoimmune diseases, allograft rejection, anti-tumor
immune responses and anti-microbial immunity. It remains
to be determined if they contribute to the molecular
mechanisms of ACD as well. In humans these lymphocytes
recognise glycolipid antigens using a TCR composed of
Vb24-Ja15 and Va11. Recognised antigens can be either
self-antigens or microbial antigens and are presented by
CD1d1. It was previously shown that terminally differen-
tiated keratinocytes from human skin increase surface
expression of CD1d [123]. A recent study examined skin
biopsies from positively patch-tested patients using
quantitative RT-PCR and immune histochemistry.
Expression of CD1d and CD161 (NKR-P1A) was found to
be upregulated in epidermal cells. The NKT frequency was
determined by immunological detection of the Va24 TCR
chain. Following exposure to PPD, NiSO4 and epoxy resin
NKT frequencies in ACD lesions were 2, 4 and 33%
respectively. In addition, the expression of the NKT cyto-
kines IFN-c and IL-4 was upregulated. The occurrence of
NKT in blood was constantly below 0.1%, confirming the
observed effects to be specific for the ACD lesions [124].
These data support the notion that keratinocytes actively
influence T cell mediated allergic immune responses in the
skin.
Cytochrome P450 in keratinocytes and antigen presenting
cells
Numerous isoforms of cytochrome P450-dependent mon-
ooxygenases (CYPs) as well as various transport systems
are expressed within the skin. The respective cells com-
prise skin cells and include keratinocytes as the major
compartment of the epidermis as well as antigen-presenting
cells such as monocytes or dendritic cells [125]. CYPs are
heme-containing enzymes catalysing the oxidative con-
version of a range of predominantly lipophilic molecules
into species that are generally more reactive and/or
hydrophilic (water soluble), thus facilitating phase II
metabolism and subsequent excretion from the body.
Keratinocytes express multiple enzymes belonging to CYP
families 1, 2 and 3, which are well known to metabolise
xenobiotics. CYPs 1A1, 1B1, 2B6, 2E1, 3A5 and 4B1 were
found to be constitutively expressed in skin-derived
keratinocytes. In addition, expression of CYP3A4 was
induced by dexamethasone and levels of CYP1A1 were
elevated following induction with benzanthracene [126].
contact
allergen
signal 3
cytokines
signal 2
costimu-
lation
MHC:antigen:TCR
signal 1
IFNγ
TNFα
IL-17
hapten-specific CTL
dendritic cell naïve Th cell polarised Th cell skin cells presenting peptide on MHC
(B)(A)
Fig. 2 Lymphocyte-mediated immune mechanisms in contact
allergy. Sensitisation phase (a). The contact allergen activates
dendritic cells in the skin via ‘pattern recognition receptors’ such as
TLRs. Subsequently naı¨ve T helper (Th) cells are polarised upon
specific recognition of the haptenated allergen by the major
histocompatibility complex (MHC), costimulatory signals and cyto-
kines such as IL-12, IL-4, IL-1b and IL-6. Elicitation phase (b).
Hapten-specific cytotoxic CD8? T lymphocytes (CTLs) release
inflammatory cytokines and induce disease-specific local skin lesions
following re-exposure of the skin to the same contact allergen
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Exon arrays show different expression patterns for CYPs
between skin and liver cells as well as for keratinocytes
and monocyte-derived DCs. Especially CYP1B1 and
CYP27A1 were primarily expressed in DCs [125].
Several studies looked at the transport systems of
keratinocytes and antigen-presenting cells because of the
inherent linkage between CYP catalysed metabolism and
cell transport. Keratinocytes and liver cells show similar
expression patters for their efflux transport systems while
differing in the expression of influx systems [127]. How-
ever, keratinocytes and antigen-presenting cells exhibit a
similar pattern of expression for their influx proteins and
differ only slightly regarding their efflux proteins. Both cell
types express organic anion-transporting polypeptides B, D
and E, the corresponding ATP-binding cassette C trans-
porters and the multi-drug resistance-associated proteins 1,
3, 4, 5 and 6 [128]. The inhibition of transport proteins
influences the phenotype of DCs and possibly the differ-
entiation of keratinocytes [129]. Furthermore transport
efficiency can influence allergen exposure and thus sensi-
tisation. The delayed efflux of eugenol metabolites leads to
an increased IL-8 expression because of high internal
eugenol concentrations [130]. Other substances require
CYP-dependent activation in order to become allergens
and thus provide conflicting data in vivo and in silico. For
carvoxime in particular uptake and subsequent CYP-
dependent metabolism are regarded as prerequisite for skin
sensitisation [131].
Common chemicals form contact allergens by autoxidation
Contact dermatitis caused by low molecular weight com-
pounds requires the formation of antigenic hapten-protein
complexes. The potential of a low molecular weight
compound to become a hapten is thus determined by its
chemical reactivity towards skin proteins. Some com-
pounds will react directly (e.g. nickel), while others require
activation, either metabolically inside the skin or externally
[132]. The latter are classified either as pro- or prehaptens,
depending on the mode of activation. Non-sensitising
compounds that require metabolic activation are prohap-
tens, while prehaptens are compounds with no or low
sensitising potential that are activated externally [133].
Examples for prehaptens are found among the unsatu-
rated hydrocarbons and ethers such as common fragrance
terpenes, diterpenes in colophony and ethoxylated surfac-
tans. Patch tests revealed some of these substances to be
potent skin sensitisers following their activation by
autoxidation. Autoxidation of limonene (from citrus) and
linalool (from lavender), two frequently used fragrances,
results in the formation of the corresponding hydroperox-
ides [134–136]. Multicentre studies imply that oxidised
limonene and oxidised linalool are among the most
common causes for ACD, while the compounds themselves
rarely cause sensitisation [22–24, 137, 138].
Prohaptens are metabolically activated in the skin and
thus activation could vary depending on the individuals’
enzymatic expression patterns. Well-known examples of
prohaptens are cinnamyl alcohol (3-phenyl-2-propen-1-ol)
and urushiols [139, 140]. Some compounds are prehaptens
as well as prohaptens. Depending on the way of activation
the resulting haptens can have different potentials for skin
sensitisation. A well-studied example is the moderate
sensitiser geraniol, which is used in the basic fragrance mix
for the diagnosis of contact allergy. Studies showed it to act
as a prehapten that is activated by autoxidation, as well as
being a prohapten when activated by CYPs. The two major
haptens formed by both processes are geranial and neral.
However, autoxidation results in the additional formation
of a sensitising hydroperoxide, while enzymatic activation
produces sensitising epoxides and aldehydes [141, 142].
Considering the importance of oxidation for the for-
mation of haptens autoxidation and CYP-mediated
metabolism should be part of the hazard identification for
potential contact allergens. This can be achieved by pre-
dicting autoxidation using structure activity relationships
(SAR) and by in vitro CYP activity assays. A recently
developed CYP cocktail is based on cutaneous CYP
enzymes and thus allows studying part of the skin metab-
olism in vitro [143]. Furthermore, diagnosis of contact
allergens should include patch tests with oxidised forms of
the corresponding substances.
Contact sensitisation: hazard identification, assessment
of potency and opportunities for the development
of alternative methods
In the past decades hundreds of chemicals have been
implicated as contact allergens. Hence there is a need to
identify potential skin sensitisers. Most approaches are
based upon an appreciation of the cellular and molecular
mechanisms involved in the acquisition of skin sensitisat-
ion. LCs are of particular interest as they are now known to
play important roles in both the initiation and orchestration
of cutaneous immune responses to chemical allergens. The
activation, mobilisation, migration and subsequent pre-
sentation of antigen in regional lymph nodes results in a
clonal expansion of allergen-responsive T lymphocytes and
the development of sensitisation [87, 144–148].
The activation and proliferation of T lymphocytes in
skin-draining lymph nodes during skin sensitisation can be
measured using the local lymph node assay (LLNA) [149].
In this assay cell turnover is measured as a function of the
incorporation of 3H-thymidine. On this basis chemicals that
elicit a three-fold or greater increase in T lymphocyte
proliferation are categorised as skin sensitisers. The LLNA
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provides a reliable test for the identification of skin-sensi-
tising chemicals and has been added to the OECD testing
guidelines [guideline 429, see ref. 150]. In addition, the
LLNA can be used for evaluation of the relative skin-
sensitising potency of contact allergens, and this in turn
provides a sound basis for the development of accurate
quantitative risk assessments. For this latter purpose EC3
values are derived from consideration of dose responses in
the assay [151, 152].
The LLNA is the most useful tool for the identification
and characterisation of skin-sensitising substances. How-
ever, there is a lack of comparable in vitro methods, and
substantial efforts have been, and are being, made world-
wide to develop alternative assays. The main challenge is
to address the required level of integration of the molecular
and cellular processes that are underlying skin sensitisat-
ion. The development of contact allergy follows a four-step
process as the allergen has to (1) achieve epidermal bio-
availability, (2) stimulate a local trauma that leads to
cytokine expression, (3) form a hapten–protein conjugate
and (4) be inherently immunogenic to induce the activation
of T lymphocytes. It will probably take several separate in
vitro assays to achieve a sufficient level of experimental
integration for these steps (I.K., personal communication).
In vitro methods as alternatives to animal testing
in predicting and characterising the allergenic
potency of chemicals
Characterising allergenic hazards and assessing allergy
risks: defining the role of alternatives
Adequate in vitro assays should allow the assessment of
allergen potency, a requirement introduced in 2009 by the
‘Globally Harmonised System’ [153]. In the absence of an
agreed standard data set, this will prove to be challenging
as the dose metrics employed in vitro need extrapolation to
match the in vivo situation.
Effective risk management requires quantitative risk
assessment and thus information about allergen potency,
i.e. EC3 values from a LLNA. Other test alternatives to the
LLNA are the Magnusson and Kligman maximisation test
and the occluded patch test of Buehler, which use guinea
pigs as test system [154, 155]. These tests predict skin-
sensitising substances (EU-label R43) with 85–90% accu-
racy, although the LLNA is the only test formally
validated. Decisions on the classification of allergens fol-
low a weight of evidence approach. They are primarily
based on the in vivo test results, but include the chemical
structure as well as clinical data in order to reduce the
number of false positives and false negatives [156]. This
strategy has been successful in identifying major skin
sensitisers. However, it fails to spot potential allergens that
fail to generate a test response of sufficient magnitude.
Skin sensitisers: chemical reactivity as a tool for hazard
and potency prediction
Chemical reactivity has been seen as a key parameter for
allergenic sensitisation since it was first discussed in the
1930s [157]. ‘Quantitative Structure Activities Relation-
ships’ (QSAR) can be used to evaluate the sensitising
potential of allergens based on physicochemical parameters
like chemical and thermodynamic constants, reactivity and
the partition coefficient. Predictions tend to be accurate for
molecules that share the same reaction mechanism. How-
ever, QSAR can be difficult for substance classes that have
more than one option on how to react with the reaction
partner, e.g. aldehydes [158, 159]. Together with nucleo-
philic proteins saturated aldehydes form Schiff bases while
a,b-unsaturated aldehydes also have the option of under-
going a Michael addition reaction [160]. In the latter case
QSAR-predicted EC3 values can differ significantly from
the ones obtained in vivo [161].
Peptide assays can be used to look into the reactivity of
potential allergens in more detail. The reactivity of
potential chemical allergens was compared using gluta-
thione and synthetic peptides containing lysine, histidine or
cysteine [162]. The assay showed the highest sensitivity
with cysteine as functional group, while histidine was the
least sensitive. Notably the assay identified some sub-
stances of low and moderate protein reactivity, which are
known to be negative in the LLNA, i.e. 2-hydroxypropyl
methacrylate, 1-bromobutane, 2-acetylcyclohexanone,
propylparaben or vanillin. However, the assay inherently
failed to detect prohaptens such as aminophenol or
3,4,dihydrocoumarin. While most skin sensitisers reacted
with cysteine, some were found to react with lysine and
others with amino groups in general. Substances binding to
any polypeptide correlated well with known potent sensi-
tisers. The best results were achieved with a prediction
system based on reactivity thresholds towards the func-
tional groups of cysteine and lysine [163].
In vitro identification of allergens
The migration of LCs is a key process during contact
sensitisation and can be used for alternative testing strate-
gies. LC migration in human skin biopsies has been
successfully used to distinguish allergens from irritants and
to assess allergen potency [164, 165]. However, as an ex
vivo method it is laborious and unsuitable for high
throughput screenings because of the limited availability of
suitable human skin.
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One alternative is the DC culture. Peripheral blood
monocytes can be differentiated to monocyte-derived
dendritic cells (MoDCs) by adding granulocyte macro-
phage colony-stimulating factor and IL-4 to the culture
medium [166]. Effects of allergens added to the maturing
MoDCs can be followed by measuring the expression
levels of the dendritic cell maturation marker CD83, the
co-stimulatory molecule CD86 and the chemokine CXCL8
[167]. Exposure to allergens like NiSO4, CrCl3, CuSO4 and
DNCB lead to elevated levels for all three markers. The
expression of CXCL8 was increased by seven out of eight
allergens, but was not affected by the addition of irritants,
i.e. DMSO, SDS or 1-propanol. This shows that the system
can be used to distinguish allergens from irritants. Other
increased markers were identified recently and include IL-
8, TRIM16 and AKR1C2 [168]. Furthermore, systems
based on DCs are a suitable tool to identify potential
contact allergens. Transcriptomic profiling of CD34? DCs
following allergen exposure resulted in the identification of
13 genes, most prominently CREM and CCR. Within the
initial set of 21 substances this marker set detected skin
sensitisers with a concordance of 89% and a specificity of
97% [169]. Intriguingly gene expression levels seem par-
tially to correlate with sensitising potency, thus allowing a
preliminary classification of the test results [170]. Another
study recently identified a biomarker signature of 200
genes in MUTZ-3 cells, following a 24 h-treatment with 20
sensitisers and 20 non-sensitisers respectively [171]. In a
comparative study MoDCs and DCs from CD34? precur-
sors recognised 76 and 67% of all tested contact allergens.
In addition, using the leukaemic THP-1 cell line, the his-
tiocytic lymphoma U-937 cell line and the acute myeloid
leukaemia MUTZ-3 cell line, 70, 83 and 100% of contact
allergens, respectively, could be identified (T.R., unpub-
lished). Two of these test systems are currently pre-
validated for regulatory purposes, namely the myeloid
‘U-937 Skin Sensitisation Test’ (MUSST) [172, 173] and
the THP-1 based ‘human Cell Line Activation Test’
(hCLAT) [174, 175]. Both test systems use the expression
of CD86 as readout for dendritic cell activation, supple-
mented by the adhesion molecule CD54 for hCLAT [176].
Comparative studies recently highlighted the use of the
latter system in regard to surfactants, a substance group for
which the LLNA is known to report false positives [177].
The T cell polarising potential of contact allergens was
investigated using oxazolone, DNCB and NiSO4. Stimu-
lation of MoDC cultures with the latter induced high levels
of the Th1 polarising cytokines TNF-a and CXCL10 [167].
Analysis of the IL-12p70 (Th1)/IL-10 (Th2) ratio showed
no effect for oxazolone, whereas DNCB enhanced a Th1
response. Notably NiSO4 induced a Th2 response, which is
the exception for contact allergens but had been suggested
earlier by clinical studies [178]. As contact allergen nickel
has the ability to activate the NF-jB pathway, which
usually leads to the release of inflammatory cytokines by
DCs [179]. Altogether it appears that the activation of DCs
is influenced by intrinsic properties of the respective
allergens. This is supported by the observation that contact
and respiratory allergens tend to cause Th1- or Th2-asso-
ciated diseases respectively [167, 178].
While DCs are crucial during initial sensitisation any
subsequent allergic reaction is caused as a consequence of
effective T cell stimulation following allergenic re-expo-
sure. Complex as it might be, stimulation of naı¨ve T cells is
thus an effective target for any in vitro testing strategy.
Naı¨ve T cells can either polarise to cytotoxic T cells (CD3?
CD8?) or Th cells (CD3? CD4?). The latter further spe-
cialise to Th1, Th2 and IL-17 releasing Th cells (Th17), or
to regulatory T cells. Two further T cell populations, Th22
and Th9, were described recently, and their role in hyper-
sensitivity remains to be determined [180–183]. Matters
are further complicated by the fact that, to an as yet
undefined extent, contact hypersensitivity is regulated by
the balance of inflammatory (Th) versus inhibitory (Treg)
cells present at the site of antigen exposure. This balance is
in turn regulated by the expression of P- and E-selectin
ligands and chemokine receptors on T cells proliferating in
the lymph nodes draining that site [Fuhlbrigge unpub-
lished, 184, 185]. Current assays thus mainly focus on the
priming of CD45RA ? T cells, using cell proliferation and
production of IFN-c or IL-5 as readouts [for a recent
review please see ref. 186]. Depletion of regulatory
CD25?- or CD4?-T cells in vivo increases the number of
IFN-c-producing T cells during sensitisation. Likewise the
sensitivity of the corresponding in vitro assays can be
increased by using systems depleted of CD25? T cells
[187, 188].
Another potential target for in vitro testing is Th cells.
Promotion of Th17 involves several cytokines (IL-6, IL-1b,
TGF-b and IL-23) and can be driven by LCs following the
stimulation of TLR 2 [189]. The involvement of TLR 2
links Th17 to dermal inflammation. Nevertheless Th17
cells seem likewise to be involved in contact allergy as
IL-17 was shown to promote type-IV hypersensitivity to
DNFB [190, 191]. Furthermore, NiSO4 stimulates LCs to
release IL-6, IL-1b and IL-23 (M.P., unpublished), and
IL-17 was previously found in nickel-specific T cells [192].
Allergens like cinnamal and DNCB fail to induce a Th17
phenotype in naı¨ve T cells, suggesting a different mecha-
nism (M.P., unpublished). Contact hypersensitivity thus
involves Th cell subpopulations, other than just Th1, which
could be considered for the design of future in vitro assays.
Other cells like NK cells are also implicated to be
effector cells for allergic inflammatory responses of the
skin [193, 194]. In T/B cell-deficient mice, NK cells can
initiate allergic responses to DNFB, oxazolone and picryl
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chloride. These responses are contact allergen-specific and
can be recalled weeks after sensitisation. In the absence of
T and B cells contact allergens thus induce memory-like
responses that depend on liver NK cells expressing the
chemokine receptor CXCR6. Further on NK cells also
infiltrate the skin of wt mice [193, 194] and humans during
allergic contact dermatitis [195]. In human contact der-
matitis they seem to amplify the allergic reaction.
Dose response and threshold issues in chemically
induced skin sensitisation and its implications
in regulatory toxicology
Assessing contact allergen potency and thresholds
in the local lymph node assay
Sensitisation to an allergen depends on its potency and
allergenic exposure in terms of frequency, duration and site.
The LLNA assesses sensitisation potency and thus allows
the identification and comparison of potential allergens
(Fig. 3). This was further demonstrated by ranking the
sensitising potential of rubber chemicals [196]. In this study
an EC3 value was estimated from a dose response curve by
fitting non-linear regression models. Uncertainty was lim-
ited to a 90% confidence interval by parametric
bootstrapping. The resulting 5th percentile of the EC3 value
from the bootstrapping method represents the dose where an
allergic reaction will occur with a 5% probability and is
similar to the benchmark dose limit (BMDL). Ultimately
the data of LLNA allow to set exposure thresholds, defining
a sensitising dose per unit area [197].
Generally LLNA thresholds correlate well with human
thresholds. A critical question is whether prolonged expo-
sure to an allergen below its threshold can cause
sensitisation. Therefore mice were subjected to an extended
LLNA, exposing them to 2,4-dinitro-1-chlorobenzene,
benzocaine and tetramethylthiuram disulfide below the
corresponding EC3 values. After 56 days the lymph
nodes showed no increased cell proliferation [198]. Similar
negative results were seen with paraformaldehyde and
hexamethylenetetramine. However, formaldehyde, 2-chloro-
N- (hydroxymethyl)acetamide and quaternium-15 showed
positive results in an extended LLNA [199]. The underly-
ing mechanisms leading to sensitisation at exposure levels
below the LLNA thresholds are unclear. Nevertheless the
results show that the use of EC3 values as thresholds for no
risk of sensitisation has to be evaluated carefully.
The LLNA as a tool to assess respiratory allergens
The LLNA has been proven to be a reliable test for the
identification of dermal sensitisers. In addition it shows
positive test results for almost all known respiratory sen-
sitisers [200]. This implies firstly that respiratory allergens
could induce allergies following dermal exposure and
secondly, that dermal tests can be used to identify potential
respiratory allergens.
This was tested by adapting the dermal LLNA to fit
respiratory exposure. BALB/c mice were exposed head/
nose-only to various allergens (respiratory and dermal)
during 3 consecutive days. Allergen exposure was at a
constant concentration for 45, 90, 180 or 360 min/day.
Three days after the last exposure cell proliferation was
determined in the mandibular lymph nodes, which drain the
respiratory tract [201]. The respiratory allergens trimellitic
anhydride (TMA), phthalic anhydride (PA), hexamethylene
diisocyanate (HDI), toluene diisocyanate (TDI) and isoph-
orone diisocyanate (IPDI) showed a more than three-fold
induction of T cell proliferation, as did the contact allergens
DNCB and oxazolone. For TDI, HDI, IPDI and oxazolone
proliferation values were even higher in the auricular lymph
nodes. It is assumed that these substances have an increased
dermal absorption due to their lipophilicity. Other sub-
stances, like the dermal allergen formaldehyde, the irritant
methylsalicylate and the unclassified trimeric IPDI, were
found to be negative in the respiratory LLNA. Altogether
the contact allergens turned out to be as potent as the
respiratory allergens in the respiratory LLNA, although the
resulting potency ranking differed from that of a dermal
LLNA [201]. Therefore all substances testing positively in
the LLNA should be considered to be a potential respiratory
allergen as well as a dermal allergen.
Risk assessment and risk management for skin-sensitising
chemicals
Quantitative risk assessment for fragrance com-
pounds Fragrances are among the most frequent
sensitisers in cosmetic products. The corresponding risk
assessments are based on the no-observed-effect-level
(NOAEL) and a qualitative assessment of exposure (i.e. the
NOAEL for substances with non-skin contact and NOAEL/
10 for substances with skin contact). This categorisation
into just two product groups prevents any further distinc-
tion of possible exposure or differences in the experienced
dose due to e.g. different applications. Hence a recent
approach suggested the use of a quantitative risk assess-
ment (QRA) for fragrance compounds [202, 203]. The
method is based on the following four steps: (1) hazard
identification, (2) dose/response relationship, (3) exposure
assessment and (4) risk characterisation. Hazard identifi-
cation reviews experimental data and clinical data to
identify the potential hazard of a fragrance substance to
cause sensitisation. The dose/response relationship then
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uses a weight of evidence approach to determine the ‘no
expected sensitisation induction level’ (NESIL) and
derives a sensitisation assessment factor (SAF) based on
the most likely scenario of exposure. The latter will include
(1) the inter-individual variability (i.e. age, gender, genet-
ics), (2) matrix effects from varying product formulations
(i.e. irritant or skin damaging) and (3) differences of the
exposure scenario in the experimental setup (i.e. applica-
tion on sensitive skin areas). Each parameter is factored
between 1 and 10, the SAF being the product of all three
factors. Division of the NESIL by the SAF aims to provide
an ‘acceptable exposure level’ (AEL). The AEL is finally
compared to the expected consumer exposure level (CEL),
based on estimates about the amount of product used, the
frequency of application and the duration of use. For safe
products the CEL should be smaller than, or equal to, the
AEL [203]. The approach was formally implemented by
the ‘International Fragrance Association’s (IFRA) code of
practice in 2006 and to date more than 80 standards have
been evaluated using QRA. However, QRA remains a
predictive model and has not been adequately assessed
against clinical or epidemiological data.
Risk management for contact allergens In the recent
years Europe has implemented a whole set of regulations
aimed at reducing the exposure of the workforce and
consumers to contact allergens. Examples are the ‘Nickel
Directive’, limiting the release of nickel in contact with
skin to 0.5 lg/(cm2 per week) [10], and the ‘Chromium
Directive’, limiting CrVI to 2 ppm in the total dry weight of
cement [29]. The directive on detergents requires the list-
ing of preservatives and listed fragrances if their content in
detergents and similar household products exceeds
100 ppm [204]. Detergents are thus treated as rinse-off
cosmetics. Furthermore, details of the product formulation
have to be released when necessary, i.e. to investigate
adverse reactions. As a result of this regulation the pre-
servative MDGN was banned from all cosmetic products in
2008. Prior to the ban cosmetic products were allowed to
contain up to 0.1% MDGN, a level that was found to cause
elicitation. A reassessment of MDGN failed to establish a
safe level of use and thus recommended the ban of the
substance [205].
A decision on the ban/restriction of PPD and other
ingredients of hair dyes is still pending. The median
prevalence of contact dermatitis against PPD in Europe is
2–6% [32]. The EU Commission’s Scientific Committee on
Consumer Products (SCCP) assessed the skin sensitising
properties of 48 hair dye substances in 2006, finding 27 of
them to be skin sensitising according to the European
classification R43. In conclusion the SCCP stated that
products containing theses substances might not be safe for
consumer use [206]. Industry has suggested to introduce
sensitivity self-testing as a regulatory requirement. How-
ever, this approach is problematic due to the possibility of
false-negative results, the induction of skin sensitisation
and ethical reasons [207]. Further, on application of hair
dyes to the skin, the product is being used for in vivo
diagnostic purposes and is thus outwith the legal frame-
work for cosmetics. Discussions continue on the safety of
PPD and similar ingredients in hair dyes
Likewise further regulation is needed for fragrance
substances. The labelling of fragrances was first addressed
in the 7th amendment of the first European cosmetics
directive [208] and subsequently included in the new
European cosmetics regulation [27]. As a consequence, the
industry introduced the concept of the aforementioned
QRA for the evaluation of fragrance substances.
Undoubtedly this will be a useful approach for new sub-
stances. However, concerns remain that QRA fails to
protect previously sensitised consumers and that aggregate
exposures through multiple products are not considered in
the basic form of the QRA. Therefore epidemiological and
clinical data continue to represent a critical decision point
in risk assessment and risk management [209].
Conclusion
Skin sensitisation and subsequent contact dermatitis is a
significant problem for consumers and workers. It is
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Fig. 3 Use of the LLNA for the regulatory risk assessment of
potential allergens. The 5th percentile of the EC3 is similar to a
probabilistic BMDL. Alternatively the respective data might be used
to estimate a threshold concentration, similar to a ‘lowest adverse
effect level’ (LOAEL)
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clear that the immune response to contact allergens is
more complex than previously thought and described.
Different allergens elicit different immune responses and
mechanisms for the activation of allergens can differ
substantially. Research efforts are underway to elucidate
the complex biochemistry and molecular biology under-
lying contact dermatitis. Several in vivo systems have
been established that are able to identify potential aller-
gens reliably and to assess their potency. At the same
time in vitro tests are developed because of public
demand to replace in vivo tests, animal welfare and
costs. However, their regulatory acceptance will depend
on a thorough validation, not only against other methods
(internal validation) but also against human observational
data from clinical epidemiological surveillance systems
(external validation). Such validation is the indispensible
gold standard for any predictive safety assessment. Leg-
islation has to focus on the protection of consumers and
workers against potential allergens, and it is adapted
continuously as our understanding of allergic contact
dermatitis progresses. In this context clinical data and the
epicutaneous patch test as published by Jadassohn more
than 100 years ago [210] are invaluable as they highlight
substances and problems missed by other approaches.
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